Roberts Glore & Co. Inc. IL Sells 1,035 Shares of Becton, Dickinson and Company (BDX)

Roberts Glore & Co. Inc. IL trimmed its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 16.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,442 shares of the medical instruments supplier’s stock after selling 1,035 shares during the quarter. Roberts Glore & Co. Inc. IL’s holdings in Becton, Dickinson and were worth $1,066,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. Almanack Investment Partners LLC. acquired a new stake in shares of Becton, Dickinson and during the first quarter worth $105,000. Mitsubishi UFJ Securities Holdings Co. Ltd. raised its holdings in shares of Becton, Dickinson and by 55.8% during the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 670 shares of the medical instruments supplier’s stock worth $131,000 after acquiring an additional 240 shares during the period. Parkside Financial Bank & Trust raised its holdings in shares of Becton, Dickinson and by 8.1% during the second quarter. Parkside Financial Bank & Trust now owns 684 shares of the medical instruments supplier’s stock worth $133,000 after acquiring an additional 51 shares during the period. Harfst & Associates Inc. raised its holdings in shares of Becton, Dickinson and by 46.4% during the second quarter. Harfst & Associates Inc. now owns 697 shares of the medical instruments supplier’s stock worth $135,000 after acquiring an additional 221 shares during the period. Finally, Financial Architects Inc raised its holdings in shares of Becton, Dickinson and by 8.0% during the second quarter. Financial Architects Inc now owns 731 shares of the medical instruments supplier’s stock worth $142,000 after acquiring an additional 54 shares during the period. 87.91% of the stock is currently owned by institutional investors.

Shares of Becton, Dickinson and Company (NYSE:BDX) traded down $1.21 during trading on Monday, hitting $220.31. 719,600 shares of the stock were exchanged, compared to its average volume of 1,325,275. Becton, Dickinson and Company has a 12 month low of $161.29 and a 12 month high of $225.23. The company has a debt-to-equity ratio of 1.48, a quick ratio of 5.01 and a current ratio of 5.56. The company has a market cap of $50,130.00, a P/E ratio of 23.22, a PEG ratio of 1.73 and a beta of 1.04.

Becton, Dickinson and (NYSE:BDX) last announced its quarterly earnings results on Thursday, November 2nd. The medical instruments supplier reported $2.40 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.37 by $0.03. Becton, Dickinson and had a net margin of 8.52% and a return on equity of 22.51%. The firm had revenue of $3.17 billion during the quarter, compared to analysts’ expectations of $3.14 billion. During the same period in the prior year, the company posted $2.12 EPS. The company’s revenue was down 2.0% on a year-over-year basis. equities analysts predict that Becton, Dickinson and Company will post 10.63 earnings per share for the current year.

In related news, EVP Linda M. Tharby sold 4,695 shares of the stock in a transaction on Tuesday, August 22nd. The shares were sold at an average price of $200.48, for a total transaction of $941,253.60. Following the transaction, the executive vice president now directly owns 18,670 shares of the company’s stock, valued at $3,742,961.60. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Gary M. Cohen sold 15,044 shares of the firm’s stock in a transaction on Tuesday, August 22nd. The shares were sold at an average price of $200.43, for a total transaction of $3,015,268.92. Following the completion of the transaction, the insider now directly owns 95,270 shares in the company, valued at $19,094,966.10. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 47,038 shares of company stock valued at $9,480,225. Corporate insiders own 1.40% of the company’s stock.

Several equities research analysts have issued reports on the stock. BidaskClub upgraded shares of Becton, Dickinson and from a “hold” rating to a “buy” rating in a research note on Monday, August 14th. Royal Bank Of Canada reiterated a “hold” rating and issued a $210.00 price target on shares of Becton, Dickinson and in a research note on Wednesday, October 25th. Zacks Investment Research upgraded shares of Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $234.00 price target on the stock in a research note on Tuesday, October 31st. Cowen and Company reiterated a “buy” rating and issued a $230.00 price target on shares of Becton, Dickinson and in a research note on Monday, August 14th. Finally, Barclays PLC reiterated an “equal weight” rating and issued a $210.00 price target (up from $205.00) on shares of Becton, Dickinson and in a research note on Thursday, August 10th. Five investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $214.79.

WARNING: This piece of content was originally posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://stocknewstimes.com/2017/11/20/roberts-glore-co-inc-il-sells-1035-shares-of-becton-dickinson-and-company-bdx.html.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply